INVO Fertility, Inc.

Snapshot

INVO is a tiny fertility-clinic operator with FY 2025 revenue of $6.8M, up modestly, but a net loss of $23.3M that dwarfs the entire top line.

What's Happening Right Now

• Tue 27th Oct '26 · Reverse split: INVO completed a 1-for-4 reverse stock split effective Oct 30, 2026, its third such split in the last 12 months, leaving roughly 1.19 million shares outstanding.
• Thu 20th Aug '26 · Clinical research: INVO's Wisconsin Fertility Institute presented five posters on platelet-rich plasma treatment outcomes at the 2026 Midwest Reproductive Symposium International.
• Mon 17th Aug '26 · Earnings beat: INVO reported Q2 2026 revenue up 17% to $2.18 million and a $0.9 million net profit (driven by a non-cash acquisition gain), with the clinic platform itself profitable on an adjusted basis before corporate overhead.
• Fri 14th Aug '26 · Going concern: INVO's Q2 2026 10-Q disclosed explicit going-concern language, with cash of $3.73 million against about $3.0 million of first-half operating cash burn and reliance on further debt or equity raises.
• Fri 7th Aug '26 · Dilution deal: INVO filed a prospectus registering up to 20 million shares for resale by Alumni Capital under a purchase agreement that could bring in up to $15 million (expandable to $50 million), with the registered shares representing about 89.7% of shares outstanding and purchases priced at discounts of 85-97% to market.